NASDAQ:NLNK - NewLink Genetics Stock Price, Price Target & More

$4.68 +0.14 (+3.08 %)

(As of 04/24/2018 01:54 PM ET)

Previous Close$4.54

Today's Range$4.45 - $4.73

52-Week Range$3.75 - $19.47

Volume509,936 shs

Average Volume1.12 million shs

Market Capitalization$166.83 million

P/E Ratio-2.02

Dividend YieldN/A

Beta1.22

About NewLink Genetics (NASDAQ:NLNK)

NewLink Genetics Corporation is a clinical-stage immuno-oncology company focused on discovering, developing and commercializing immunotherapeutic products for the treatment of cancer. The Company's portfolio includes biologic and small-molecule immunotherapy product candidates for a range of oncology indications. Its biologic product candidates are based on its HyperAcute Cellular Immunotherapy technology, which is designed to stimulate the human immune system to attack cancer cells. Its additional HyperAcute Cellular Immunotherapy product candidates in clinical development include tergenpumatucel-L and dorgenmeltucel-L for patients with advanced lung cancer and melanoma, respectively. Additionally, it has two small-molecule product candidates in clinical development: GDC-0919 and indoximod. These product candidates are indoleamine-2, 3-dioxygenase (IDO) pathway inhibitors and focus on breaking the immune system's tolerance to cancer.

Receive NLNK News and Ratings via Email

Sign-up to receive the latest news and ratings for NLNK and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations

Sub-IndustryBiotechnology

SectorMedical

SymbolNASDAQ:NLNK

CUSIP65151110

Webwww.newlinkgenetics.com

Phone515-296-5555

Debt

Debt-to-Equity RatioN/A

Current Ratio7.96%

Quick Ratio7.96%

Price-To-Earnings

Trailing P/E Ratio-2.02

Forward P/E Ratio-2.02

P/E GrowthN/A

Sales & Book Value

Annual Sales$28.71 million

Price / Sales6.06

Cash FlowN/A

Price / CashN/A

Book Value$4.09 per share

Price / Book1.14

Profitability

EPS (Most Recent Fiscal Year)($2.30)

Net Income$-71,950,000.00

Net Margins-250.60%

Return on Equity-60.60%

Return on Assets-47.48%

Miscellaneous

Employees76

Outstanding Shares37,160,000

How to Become a New Pot Stock Millionaire

NewLink Genetics (NASDAQ:NLNK) Frequently Asked Questions

What is NewLink Genetics' stock symbol?

NewLink Genetics trades on the NASDAQ under the ticker symbol "NLNK."

How were NewLink Genetics' earnings last quarter?

NewLink Genetics Corp (NASDAQ:NLNK) issued its earnings results on Thursday, March, 1st. The biotechnology company reported ($0.37) earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of ($0.69) by $0.32. The biotechnology company earned $10.10 million during the quarter, compared to the consensus estimate of $2.72 million. NewLink Genetics had a negative net margin of 250.60% and a negative return on equity of 60.60%. View NewLink Genetics' Earnings History.

When is NewLink Genetics' next earnings date?

NewLink Genetics is scheduled to release their next quarterly earnings announcement on Thursday, May, 3rd 2018. View Earnings Estimates for NewLink Genetics.

What price target have analysts set for NLNK?

6 Wall Street analysts have issued 1 year price objectives for NewLink Genetics' stock. Their predictions range from $5.00 to $25.00. On average, they expect NewLink Genetics' stock price to reach $13.50 in the next year. View Analyst Ratings for NewLink Genetics.

What are Wall Street analysts saying about NewLink Genetics stock?

Here are some recent quotes from research analysts about NewLink Genetics stock:

1. Cantor Fitzgerald analysts commented, "Data from a Phase I study of indoximod in diffuse intrinsic pontine glioma (DIPG) presented at AACR were positive, in our view, but given the recent failure of Incyte’s (INCY, NC) epacadostat, we do not believe that is likely to sway investors at this point." (4/16/2018)
2. According to Zacks Investment Research, "NewLink Genetics Corporation is a biopharmaceutical company which focuses on discovering, developing and commercializing immunotherapeutic products for cancer treatment. Its portfolio also includes biologic and small-molecule immunotherapy products used for the treatment of oncology indications. NewLink Genetics Corporation is headquartered in Ames, Iowa. " (1/4/2018)

Who are some of NewLink Genetics' key competitors?

Some companies that are related to NewLink Genetics include AMAG Pharmaceuticals (AMAG), Endocyte (ECYT), Lannett (LCI), Reata Pharmaceuticals (RETA), Dicerna Pharmaceuticals (DRNA), Ziopharm Oncology (ZIOP), Geron (GERN), Rhythm Pharmaceuticals (RYTM), Arrowhead Pharmaceuticals (ARWR), Achaogen (AKAO), AC Immune (ACIU), Keryx Biopharmaceuticals (KERX), Five Prime Therapeutics (FPRX), Rigel Pharmaceuticals (RIGL) and Odonate Therapeutics (ODT).

Who are NewLink Genetics' key executives?

NewLink Genetics' management team includes the folowing people:

Charles J. Link Jr. M.D., Chairman of the Board, Chief Executive Officer, Chief Scientific Officer (Age 56)
Nicholas N. Vahanian M.D., President (Age 47)
John Bell Henneman III, Chief Financial Officer, Secretary (Age 55)
Eugene P. Kennedy M.D., Chief Medical Officer (Age 49)
Brian Wiley, Chief Commercial Officer (Age 48)
Thomas A. Raffin M.D., Lead Independent Director (Age 68)
Paolo Pucci, Director (Age 56)
Paul R. Edick, Independent Director (Age 62)
Ernest J. Talarico III, Independent Director (Age 44)
Lota S. Zoth CPA, Independent Director (Age 57)

Has NewLink Genetics been receiving favorable news coverage?

News coverage about NLNK stock has trended somewhat positive on Tuesday, according to Accern. The research group scores the sentiment of press coverage by monitoring more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. NewLink Genetics earned a media sentiment score of 0.03 on Accern's scale. They also gave media coverage about the biotechnology company an impact score of 46.08 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company's share price in the next several days.

How do I buy shares of NewLink Genetics?

Shares of NLNK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is NewLink Genetics' stock price today?

One share of NLNK stock can currently be purchased for approximately $4.68.

How big of a company is NewLink Genetics?

NewLink Genetics has a market capitalization of $166.83 million and generates $28.71 million in revenue each year. The biotechnology company earns $-71,950,000.00 in net income (profit) each year or ($2.30) on an earnings per share basis. NewLink Genetics employs 76 workers across the globe.

How can I contact NewLink Genetics?

NewLink Genetics' mailing address is 2503 SOUTH LOOP DRIVE SUITE 5100, AMES IA, 50010. The biotechnology company can be reached via phone at 515-296-5555 or via email at [email protected]

MarketBeat Community Rating for NewLink Genetics (NLNK)

Community Ranking:		3.0 out of 5 ( )
Outperform Votes:		285 (Vote Outperform)
Underperform Votes:		191 (Vote Underperform)
Total Votes:		476

MarketBeat's community ratings are surveys of what our community members think about NewLink Genetics and other stocks. Vote "Outperform" if you believe NLNK will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NLNK will underperform the S&P 500 over the long term. You may vote once every thirty days.

NewLink Genetics (NASDAQ:NLNK) Price Target and Consensus Rating

(How are Consensus Ratings Calculated?)

6 Wall Street analysts have issued ratings and price targets for NewLink Genetics in the last 12 months. Their average twelve-month price target is $13.50, suggesting that the stock has a possible upside of 188.46%. The high price target for NLNK is $25.00 and the low price target for NLNK is $5.00. There are currently 5 hold ratings and 1 buy rating for the stock, resulting in a consensus rating of "Hold."

	Today	30 Days Ago	90 Days Ago	180 Days Ago
Consensus Rating:	Hold	Buy	Buy	Buy
Consensus Rating Score:	2.17	3.00	3.00	3.00
Ratings Breakdown:	0 Sell Rating(s) 5 Hold Rating(s) 1 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 0 Hold Rating(s) 6 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 0 Hold Rating(s) 6 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 0 Hold Rating(s) 6 Buy Rating(s) 0 Strong Buy Rating(s)
Consensus Price Target:	$13.50	$23.6667	$25.6667	$25.8333
Price Target Upside:	188.46% upside	211.81% upside	203.57% upside	129.63% upside

NewLink Genetics (NASDAQ:NLNK) Consensus Price Target History

Price Target History for NewLink Genetics (NASDAQ:NLNK)

NewLink Genetics (NASDAQ:NLNK) Analyst Ratings History

Show:

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price
4/16/2018	Cantor Fitzgerald	Set Price Target	Hold	$7.00	High
4/12/2018	Jefferies Group	Reiterated Rating	Hold		High
4/9/2018	Robert W. Baird	Downgrade	Outperform -> Neutral	$22.00 -> $5.00	High
4/6/2018	Bank of America	Downgrade	Buy -> Neutral		High
4/6/2018	SunTrust Banks	Downgrade	Buy -> Hold	$19.00 -> $5.00	High
3/2/2018	Stifel Nicolaus	Reiterated Rating	Buy	$25.00 -> $21.00	High
5/10/2016	Mizuho	Lower Price Target	Buy	$52.00 -> $20.00	N/A

(Data available from 4/24/2016 forward)

NewLink Genetics (NASDAQ:NLNK) Earnings History and Estimates Chart

Earnings by Quarter for NewLink Genetics (NASDAQ:NLNK)

NewLink Genetics (NASDAQ:NLNK) Earnings Estimates

2018 EPS Consensus Estimate: ($2.52)

Quarter	Number of Estimates	Low Estimate	High Estimate	Average Estimate
Q1 2018	2	($0.63)	($0.51)	($0.57)
Q2 2018	1	($0.66)	($0.66)	($0.66)
Q3 2018	2	($0.69)	($0.62)	($0.66)
Q4 2018	1	($0.63)	($0.63)	($0.63)

NewLink Genetics (NASDAQ NLNK) Earnings History by Quarter

Date	Quarter	Consensus Estimate	Actual EPS	Revenue Estimate	Actual Revenue	Release Link	Conference Call
5/3/2018		($0.55)					N/A
3/1/2018	Q4 2017	($0.69)	($0.37)	$2.72 million	$10.10 million	View	N/A
11/2/2017	Q3 2017	($0.74)	($0.69)	$2.38 million	$5.48 million	View	N/A
7/28/2017	Q2 2017	($0.78)	($0.5720)	$2.65 million	$10.37 million	View	N/A
5/4/2017	Q1 2017	($0.82)	($0.72)	$2.68 million	$2.76 million	View	Listen
2/28/2017	Q416	($0.66)	($0.4630)	$4.31 million	$12.70 million	View	Listen
11/1/2016	Q3	($0.60)	($0.54)	$3.83 million	$15.35 million	View	N/A
7/29/2016	Q216	($0.77)	($1.12)	$4.81 million	$2.01 million	View	Listen
4/29/2016	Q116	($1.70)	($0.82)	$2.08 million	$4.34 million	View	Listen
2/29/2016	Q415	($0.92)	($0.75)	$4.89 million	$6.06 million	View	Listen
11/3/2015	Q315	($0.66)	($0.55)	$9.01 million	$14.21 million	View	N/A
7/31/2015	Q215	($0.70)	($0.49)	$4.32 million	$7.45 million	View	Listen
5/5/2015	Q115	($0.22)	$0.35	$12.78 million	$39.20 million	View	N/A
2/26/2015	Q414	($0.78)	$4.05	$2.98 million	$159.25 million	View	N/A
11/6/2014	Q314	($0.41)	($0.20)	$0.31 million	$2.80 million	View	N/A
8/5/2014	Q214	($0.42)	($0.33)	$0.30 million	$0.21 million	View	N/A
5/6/2014	Q1 2014	($0.37)	($0.33)	$0.31 million	$0.33 million	View	N/A
3/11/2014		($0.37)	($0.31)	$0.33 million	$0.29 million	View	N/A
11/11/2013	Q3	($0.3250)	($0.32)	$0.33 million	$0.27 million	View	N/A
8/7/2013	Q213	($0.32)	($0.28)	$0.59 million	$0.2320 million	View	N/A
5/6/2013	Q113	($0.28)	($0.33)	$0.41 million	$0.3020 million	View	N/A
2/28/2013	Q4 2012	($0.33)	($0.30)			View	N/A
10/31/2012	Q3 2012	($0.32)	($0.28)			View	N/A
8/14/2012	Q2 2012	($0.31)	($0.31)			View	N/A
5/10/2012	Q1 2012	($0.36)	($0.24)			View	N/A
3/29/2012	Q4 2011	($0.36)	($0.44)			View	N/A
12/16/2011	Q3 2011		($1.09)			View	N/A

(Earnings results data provided by Zacks Investment Research)

NewLink Genetics (NASDAQ:NLNK) Dividend History by Quarter

Announced	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date

(Data available from 1/1/2013 forward)

NewLink Genetics (NASDAQ NLNK) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 12.30%
Institutional Ownership Percentage: 65.00%

Insider Trading History for NewLink Genetics (NASDAQ:NLNK)

Institutional Ownership by Quarter for NewLink Genetics (NASDAQ:NLNK)

NewLink Genetics (NASDAQ NLNK) Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
11/21/2017	Carl W. Langren	Insider	Sell	2,229	$9.05	$20,172.45
10/6/2017	Stine Seed Farm, Inc.	Major Shareholder	Buy	780,487	$10.25	$7,999,991.75	7,857,732
3/15/2016	Charles J Jr. Link	CEO	Sell	25,000	$17.86	$446,500.00	297,756
1/6/2016	Charles J. Jr. Link	CEO	Sell	25,000	$32.53	$813,250.00	342,756
1/5/2016	Brian Wiley	VP	Sell	1,295	$34.99	$45,312.05	19,942
1/5/2016	Carl W. Langren	insider	Sell	1,095	$34.97	$38,292.15	13,465
1/5/2016	Charles J. Jr. Link	CEO	Sell	5,001	$35.06	$175,335.06	342,756
1/5/2016	John B. Henneman III	CFO	Sell	175	$35.74	$6,254.50	62,316
10/7/2015	Charles J. Jr. Link	CEO	Sell	10,000	$35.16	$351,600.00	371,118
10/5/2015	Charles J. Jr. Link	CEO	Sell	15,000	$37.36	$560,400.00	371,118
7/13/2015	Joseph Saluri	Director	Sell	5,000	$50.42	$252,100.00
7/6/2015	Charles J Jr. Link	CEO	Sell	20,000	$44.65	$893,000.00

(Data available from 1/1/2013 forward)

NewLink Genetics (NASDAQ NLNK) News Headlines

Source:

Date	Headline
	NewLink Genetics to Host Its First Quarter 2018 Financial Results Conference Call on May 3, 2018 finance.yahoo.com - April 20 at 5:21 PM
	NewLink Genetics (NLNK) Downgraded to Sell at Zacks Investment Research www.americanbankingnews.com - April 18 at 8:34 PM
	NewLink Genetics Describes the Differentiated Mechanism of Action of Indoximod in AACR Poster Presentation finance.yahoo.com - April 17 at 5:54 PM
	Zacks: Analysts Expect NewLink Genetics Corp (NLNK) Will Post Quarterly Sales of $5.78 Million www.americanbankingnews.com - April 17 at 1:50 AM
	NewLink down 8% after bailing on indoximod in melanoma study seekingalpha.com - April 16 at 5:24 PM
	Early data indicate indoximod has clinical activity when used in combination therapies beyond PD-1 inhibition globenewswire.com - April 16 at 8:16 AM
	NewLink Genetics' (NLNK) Hold Rating Reaffirmed at Cantor Fitzgerald www.americanbankingnews.com - April 16 at 7:11 AM
	Analysts Anticipate NewLink Genetics Corp (NLNK) Will Announce Earnings of -$0.55 Per Share www.americanbankingnews.com - April 15 at 11:10 PM
	NewLink Genetics Announces Initial Phase 1 Data with Indoximod Plus Radiation and Chemotherapy for www.nasdaq.com - April 15 at 6:35 PM
	Jefferies Group Reiterates "Hold" Rating for NewLink Genetics (NLNK) www.americanbankingnews.com - April 12 at 11:17 AM
	NewLink Genetics' Potential Catalysts Not Enough To Justify A Bullish Stance, Baird Says In Downgrade finance.yahoo.com - April 10 at 8:27 AM
	NewLink Shares Plunge After Incyte & Merck's Study Fails finance.yahoo.com - April 10 at 8:27 AM
	New Research Coverage Highlights Golden Star Resources, Ryanair, Sasol, Access National, NewLink Genetics, and Canadian Pacific Railway — Consolidated Revenues, Company Growth, and Expectations for 2018 finance.yahoo.com - April 10 at 8:27 AM
	NewLink Shares Plunge After Incyte & Merck's Study Fails www.zacks.com - April 9 at 5:21 PM
	UPDATE: Baird Downgrades NewLink Genetics (NLNK) to Neutral Citing IDO Concerns www.streetinsider.com - April 9 at 5:21 PM
	UPDATE: Cantor Fitzgerald Downgrades NewLink Genetics (NLNK) to Neutral www.streetinsider.com - April 9 at 5:21 PM
	NewLink Genetics (NLNK) Rating Lowered to Hold at Robert W. Baird www.americanbankingnews.com - April 9 at 7:55 AM
	NewLink Genetics (NLNK) Lowered to "Hold" at Cantor Fitzgerald www.americanbankingnews.com - April 9 at 7:55 AM
	SunTrust Robinson Humphrey Downgrades NewLink Genetics (NLNK) to Hold www.streetinsider.com - April 7 at 8:25 AM
	NewLink Genetics (NLNK) Downgraded by Jefferies Group to "Hold" www.americanbankingnews.com - April 6 at 9:16 PM
	NewLink Genetics shares plummet 39% after Merck, Incyte trial failure www.marketwatch.com - April 6 at 5:41 PM
	Incyte's late-stage epacadostat flop pressures NewLink Genetics, down 32% premarket seekingalpha.com - April 6 at 5:41 PM
	NewLink Genetics Announces Review of Clinical Programs www.nasdaq.com - April 6 at 5:41 PM
	Why Incyte and NewLink Genetics Crashed Today finance.yahoo.com - April 6 at 5:41 PM
	NewLink Genetics (NLNK) Lowered to "Neutral" at Bank of America www.americanbankingnews.com - April 6 at 4:14 PM
	SunTrust Banks Downgrades NewLink Genetics (NLNK) to Hold www.americanbankingnews.com - April 6 at 1:23 PM
	Cantor Fitzgerald Analysts Give NewLink Genetics (NLNK) a $26.00 Price Target www.americanbankingnews.com - April 6 at 12:11 PM
	Technical Perspectives on Biotech Stocks -- Neptune Technologies & Bioressources, Neuralstem, NewLink Genetics, and OHR Pharma www.prnewswire.com - April 5 at 6:27 AM
	NewLink Genetics Announces Participation at The H.C. Wainwright Annual Global Life Sciences Conference finance.yahoo.com - April 3 at 5:35 PM
	NewLink Genetics (NLNK) Upgraded to Buy by Zacks Investment Research www.americanbankingnews.com - April 1 at 5:22 PM
	NewLink Genetics Corp (NLNK) Given Consensus Recommendation of "Buy" by Analysts www.americanbankingnews.com - April 1 at 1:30 PM
	Zacks Investment Research Downgrades NewLink Genetics (NLNK) to Hold www.americanbankingnews.com - April 1 at 12:58 PM
	$5.78 Million in Sales Expected for NewLink Genetics Corp (NLNK) This Quarter www.americanbankingnews.com - April 1 at 5:51 AM
	NewLink Genetics (NLNK) PT Set at $26.00 by Cantor Fitzgerald www.americanbankingnews.com - March 30 at 12:05 PM
	NewLink Genetics Target of Unusually High Options Trading (NLNK) www.americanbankingnews.com - March 30 at 7:06 AM
	-$0.55 EPS Expected for NewLink Genetics Corp (NLNK) This Quarter www.americanbankingnews.com - March 30 at 3:22 AM
	Options Traders Expect Huge Moves in NewLink Genetics (NLNK) Stock March 29, 2018 www.zacks.com - March 29 at 5:30 PM
	NewLink Genetics (NLNK) Names Chad A. Johnson to Board - StreetInsider.com www.streetinsider.com - March 23 at 8:19 AM
	NewLink Genetics Appoints Chad A. Johnson to Board of Directors - GlobeNewswire (press release) globenewswire.com - March 22 at 8:26 AM
	NewLink Genetics Appoints Chad A. Johnson to Board of Directors finance.yahoo.com - March 21 at 5:37 PM
	NewLink Genetics Announces Presentation of Abstracts at AACR ... - GlobeNewswire (press release) globenewswire.com - March 15 at 8:17 AM
	Factors of Influence in 2018, Key Indicators and Opportunity within NewLink Genetics, Chipmos Technologies, Helen of Troy, InterDigital, Summit Therapeutics, and Kornit Digital — New Research Emphasizes Economic Growth finance.yahoo.com - March 15 at 8:17 AM
	NewLink Genetics Announces Presentation of Abstracts at AACR Annual Meeting finance.yahoo.com - March 14 at 7:06 PM
	NewLink Genetics to Participate in Upcoming Investor Conferences - GlobeNewswire (press release) globenewswire.com - March 13 at 8:26 AM
	Analysts Expect NewLink Genetics Corp (NLNK) Will Announce Earnings of -$0.55 Per Share www.americanbankingnews.com - March 12 at 11:06 PM
	Stock Traders Purchase Large Volume of NewLink Genetics Put Options (NLNK) www.americanbankingnews.com - March 8 at 8:14 AM
	NewLink Genetics Corp (NLNK) Receives Consensus Recommendation of "Buy" from Analysts www.americanbankingnews.com - March 7 at 1:51 PM
	FY2018 Earnings Estimate for NewLink Genetics Corp (NLNK) Issued By Cantor Fitzgerald www.americanbankingnews.com - March 7 at 11:53 AM
	NewLink Genetics Corp (NLNK) Expected to Earn Q1 2018 Earnings of ($0.51) Per Share www.americanbankingnews.com - March 5 at 1:48 AM
	Hudson Bay Capital Management LP Purchases New Holdings in NewLink Genetics Corp (NLNK) www.americanbankingnews.com - March 3 at 12:51 PM

NewLink Genetics (NASDAQ:NLNK) SEC Filings

Form Type:

Ownership Filings:

This page is loading this company's SEC Filings. Please wait...

NewLink Genetics (NASDAQ:NLNK) Income Statement, Balance Sheet and Cash Flow Statement

NewLink Genetics (NASDAQ NLNK) Stock Chart for Tuesday, April, 24, 2018

Loading chart…

This page was last updated on 4/24/2018 by MarketBeat.com Staff